scholarly journals Features of cough therapy in children

2021 ◽  
pp. 102-109
Author(s):  
I. N. Kholodova
Keyword(s):  
Upper Respiratory Tract ◽  
Efficacy And Safety ◽  
Respiratory Problems ◽  
Antitussive Effect ◽  
Proven Efficacy ◽  
Complicated Course ◽  
Combined Action ◽  
Tract Infections ◽  
Antitussive Drugs

This article discusses the problem of cough in children as one of the symptoms of a complicated course of acute respiratory infection. The data on the peculiarities of the course of cough in children depending on the cause, the level of damage, and age are presented. Virulence of infectious agents, immune status, and the child’s constitution may influence the development of local inflammation covering the tonsils, adenoids, pharynx, larynx. The study of respiratory problems in children remains relevant due to the need to improve therapy tactics and rehabilitation after an infection. Acute upper respiratory tract infections affect about 23 million children annually, which is 52% of the total morbidity of children and adolescents aged 0-17 years. Various therapeutic options are discussed. Thus, central drugs have a direct antitussive effect and cause inhibition of the cough center: narcotic antitussive drugs, such as codeine-containing drugs; non-narcotic antitussive drugs (glaucine hydrochloride, butamirate citrate, etc.). Peripheral medications reduce the sensitivity of cough afferent receptors and act on the mucosa of the airways. There are drugs of combined action, as well as bronchodilators, mucoactive drugs, and chest cough sets. Particular attention is paid to the multicomponent drug, which has a complex anti-inflammatory, antitussive and antimicrobial action in cough. The results of various foreign and domestic studies on the efficacy and safety of this drug are given. The necessity of early treatment is emphasized to improve the quality of life of patients and to prevent the formation of chronic bronchial processes. It is concluded that for the treatment of children it is necessary to choose the best drugs. It should be drugs that have proven efficacy and safety, and most importantly - they should be registered for use in the Russian Federation.

Nasal disease and quality of life in athletes

2018 ◽  
Vol 132 (9) ◽  
pp. 812-815
Author(s):  
A C Walker ◽  
P Surda ◽  
M Rossiter ◽  
S A Little
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Nasal Symptoms ◽  
Nasal Disease ◽  
Upper Respiratory ◽  
Tract Infections

AbstractObjectivesNasal disease imposes a significant disease burden upon the individual in the general population, but is relatively under studied in athletes. This study sought to define the frequency of nasal symptoms in the active population, and to quantify the impact of these symptoms on quality of life and on the frequency of upper respiratory tract infections.ResultsA total of 296 participants completed the study (246 athletes and 50 sedentary controls). Nasal symptoms were significantly more frequent in the active group than in the sedentary controls (70 per cent vs 52 per cent). Upper respiratory tract infections were significantly more common in athletes with regular nasal symptoms than in athletes without nasal symptoms. Quality-of-life scores, as measured by the 22-item Sino-Nasal Outcome Test, were significantly worse in athletes with regular nasal symptoms.ConclusionThis study suggests that regular exercise is associated with a significant increase in the prevalence of troubling nasal symptoms, and nasal symptoms in athletes are associated with increased susceptibility to upper respiratory tract infections. Quality of life was negatively affected, confirming the importance of nasal health to athlete welfare.

scholarly journals Antibiotic prescribing quality for children in primary care: an observational study

2018 ◽  
Vol 68 (667) ◽  
pp. e90-e96 ◽  
Author(s):  
Megan Rose Williams ◽  
Giles Greene ◽  
Gurudutt Naik ◽  
Kathryn Hughes ◽  
Christopher C Butler ◽  
...  
Keyword(s):  
Primary Care ◽  
Young Children ◽  
Otitis Media ◽  
Descriptive Analysis ◽  
Inappropriate Prescribing ◽  
Antibiotic Prescribing ◽  
Upper Respiratory Tract ◽  
Tract Infections ◽  
Disease Specific

BackgroundOveruse and inappropriate prescribing of antibiotics is driving antibiotic resistance. GPs often prescribe antibiotics for upper respiratory tract infections (URTIs) in young children despite their marginal beneficial effects.AimTo assess the quality of antibiotic prescribing for common infections in young children attending primary care and to investigate influencing factors.Design and settingAn observational, descriptive analysis, including children attending primary care sites in England and Wales.MethodThe Diagnosis of Urinary Tract infection in Young children study collected data on 7163 children aged <5 years, presenting to UK primary care with an acute illness (<28 days). Data were compared with the European Surveillance of Antimicrobial Consumption Network (ESAC-Net) disease-specific quality indicators to assess prescribing for URTIs, tonsillitis, and otitis media, against ESAC-Net proposed standards. Non-parametric trend tests and χ2tests assessed trends and differences in prescribing by level of deprivation, site type, and demographics.ResultsPrescribing rates fell within the recommendations for URTIs but exceeded the recommended limits for tonsillitis and otitis media. The proportion of children receiving the recommended antibiotic was below standards for URTIs and tonsillitis, but within the recommended limits for otitis media. Prescribing rates increased as the level of deprivation decreased for all infections (P<0.05), and increased as the age of the child increased for URTIs and tonsillitis (P<0.05). There were no other significant trends or differences.ConclusionThe quality of antibiotic prescribing in this study was mixed and highlights the scope for future improvements. There is a need to assess further the quality of disease-specific antibiotic prescribing in UK primary care settings using data representative of routine clinical practice.

Quality of life in patients with smell loss due to upper respiratory tract infections

2011 ◽  
Vol 32 (6) ◽  
pp. 504-510 ◽  
Author(s):  
Adolfo Toledano ◽  
Gil Rodríguez ◽  
Ana María Martín ◽  
Tomás Onrubia ◽  
Néstor Galindo
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Tract Infections ◽  
Smell Loss

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis

2009 ◽  
Vol 36 (6) ◽  
pp. 1256-1264 ◽  
Author(s):  
BEN DIJKMANS ◽  
PAUL EMERY ◽  
MARKKU HAKALA ◽  
MARJATTA LEIRISALO-REPO ◽  
EMILIO MARTIN MOLA ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Safety Data ◽  
Blind Study ◽  
Double Blind Study ◽  
Upper Respiratory Tract ◽  
Efficacy And Safety ◽  
Open Label ◽  
Double Blind ◽  
Open Label Extension ◽  
Tract Infections

Objective.To evaluate the 2-year efficacy and safety of etanercept in patients with ankylosing spondylitis (AS).Methods.A 96-week open-label extension study, which followed a 12-week double-blind placebo-controlled trial, was designed to provide longterm efficacy and safety data, including radiographic outcomes, for patients treated with etanercept 25 mg twice weekly (NCT00421980). In all, 81 patients were enrolled (96% of the participants from the double-blind study). Key efficacy measures included improvement using the Assessment in Ankylosing Spondylitis 20% (ASAS20) criteria, the Bath Ankylosing Spondylitis Functional Index (BASFI), and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Radiographic progression was evaluated using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) method. Paired t tests were used to test within-group changes from baseline.Results.The percentage of responders, by ASAS20 criteria, remained relatively constant in patients who received etanercept during the 12-week double-blind study (60% at Week 0 and 83% at Week 96 of the open-label extension); more patients from the placebo group became responders after being switched to etanercept (23% and 74%, respectively). A similar trend was also observed using the ASAS40 and ASAS5/6 criteria, the BASFI, and the BASDAI. Most patients had no change from baseline in mSASSS values. Etanercept was well tolerated; the most frequent adverse events were injection site reactions (n = 30; 37.0%) and headache (n = 18; 22.2%), and the most frequent infections were upper respiratory tract infections (n = 43; 53.1%) and flu syndrome (n = 22; 27.2%).Conclusion.For 2 years, etanercept was clinically effective and well tolerated, with no unexpected safety findings.

Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections

2012 ◽  
Vol 39 (5) ◽  
pp. 512-518 ◽  
Author(s):  
Makoto Ito ◽  
Yumiko Maruyama ◽  
Shigeyuki Murono ◽  
Naohiro Wakisaka ◽  
Satoru Kondo ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Efficacy And Safety ◽  
Upper Respiratory ◽  
Tract Infections

scholarly journals Ectomesenchymal Chondromyxoid Tumour of the Dorsal Tongue Presenting with Impaired Speech

2016 ◽  
Vol 2016 ◽  
pp. 1-4
Author(s):  
Laura A. Schep ◽  
Martin J. Bullock ◽  
S. Mark Taylor
Keyword(s):  
Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Anterior Dorsal ◽  
Dorsal Tongue ◽  
Upper Respiratory ◽  
Clinical Photograph ◽  
Tract Infections ◽  
Impaired Speech ◽  
Slow Growing

Ectomesenchymal chondromyxoid tumours (ECTs) are rare mesenchymal soft tissue neoplasms that typically present as a slow-growing asymptomatic mass on the anterior dorsum of the tongue. Our patient presented with impaired speech articulation and pain associated with upper respiratory tract infections when the lesion on his dorsal tongue would swell, and he would accidentally bite down on it. Microscopically, ECTs appear as unencapsulated, well-circumscribed proliferations of uniform round to fusiform cells embedded within chondromyxoid matrices. Most cases of ECT have been detected in the third to the sixth decades of life, with no sex preference. ECT may cause a range of symptoms that negatively impact patients’ quality of life, including pain, dysphagia, odynophagia, bleeding, and, in the case of our patient, impairment of speech. We provide a unique preoperative clinical photograph and case description that should help readers in recognizing this neoplasm. Considering the rarity of ECT presenting clinically as well as in the literature, we believe this report will add to our growing understanding of ECT and its management. We report a case of ECT presenting on the anterior dorsal tongue that was successfully surgically resected under local anesthesia with clear margins, accompanied by a review of the pertinent literature.

Sign in / Sign up

Export Citation Format

Share Document